Safety of Inhaled Insulin in Adults with Diabetes

Abstract

Get full access to this article

View all access options for this article.

References

Simons

, Krishnan

. The economic value of lamotrigine as a mood stabilizer: A US managed care perspective. Manag Care Interface, 2004; 17(12):44–49.

History of Real-World Evidence. Health from Data. Available from: https://www.medaffcon.com/history-of-real-world-evidence/ [Last accessed: September 21, 2025].

Cowart

, Everich

, Flores

, et al. Real-world incidence of lung malignancy and chronic obstructive pulmonary disease with inhaled insulin in people with diabetes. Diabetes Technol Ther, 2026; 28(3):201–205; doi: 10.1177/15209156251387102

Caffrey

. Patients report barriers to getting Afrezza, but A1C results are worth it. Patients Report Barriers to Getting Afrezza, but A1C Results Are Worth It. AJMC. Available from: https://www.ajmc.com/view/patients-report-barriers-to-getting-afrezza-but-a1c-results-are-worth-it [Last accessed: September 21, 2025].

FDA. Afrezza Prescribing Information.

McGill

, Peters

, Buse

, et al. Comprehensive pulmonary safety review of inhaled technosphere(®) insulin in patients with diabetes mellitus. Clin Drug Investig, 2020; 40(10):973–983.